Advanced searches left 3/3

Metformin Polycystic - Europe PMC

Summarized by Plex Scholar
Last Updated: 05 May 2022

* If you want to update the article please login/register

Combination of alpha lipoic acid and metformin supplement improve assisted reproductive technologies outcomes in polycystic ovary syndrome patients.

In polycystic ovary syndrome women undergoing intracytoplasmic sperm injections, we investigated the effects of metformin in combination with alpha lipoic acid on hormonal and biochemical parameters. This experimental pilot study with a randomized format was carried out on 40 PCOS women in two groups: the MET group, which gave 1,500 mg/day MET, and the MET+ALA group. When compared to the MET group, MET+ALA significantly increased the number of mature oocytes and the rate of fertilization. Also, the malondialdehyde level in the MET+ALA group decreased significantly in the MET+ALA group, and the total antioxidant capacity level increased noticeably in the MET+ALA group relative to the MET group. The pregnancy results showed that there was no significant difference between the control and study groups in terms of biochemical pregnancy, clinical pregnancy, miscarriage, and live births. The combination of MET+ALA therapy may have the ability to reduce PCOS-related issues while also improving oocyte and embryo quality.

Source link: https://europepmc.org/article/MED/35501295


A decrease in cluster of differentiation 2 expression on natural killer cells is associated with polycystic ovary syndrome but not influenced by metformin in a mouse model†.

Leguan Affectment Natural killer cells from the peripheral blood and spleen are the source from which various tissues replenish their immune cell populations. In a PCOS mouse model, we investigated the prevalence of peripheral blood and splenic NK cells and their CD2 and CD94 expression profiles, as well as testing whether metformin could reverse these effects. The expressions of CD2 and CD94 on peripheral blood and splenic NK cells were determined by flow cytometry. PCOS mice had a low surface-density of CD2 on peripheral blood NK cells and a reduced number of CD2+ splenic NK cells, as shown by the table below. Conclusions The results of our studies showed that PCOS was associated with an elevated splenic NK cell count and that of metformin, as well as an increased splenic NK cell reserve in PCOS conditions.

Source link: https://europepmc.org/article/MED/35098296


The Effects of Letrozole and Metformin Combined with Targeted Nursing Care on Ovarian Function, LH, and FSH in Infertile Patients with Polycystic Ovary Syndrome.

Background polycystic ovary syndrome is a common gynecological disorder in women of reproductive age and is the most common cause of female infertility. This research sought to investigate the effects of letrozole and metformin in infants with PCOS, as well as targeted nursing on ovarian function, LH, and FSH in infants with PCOS. Methods An total of 72 infertile patients with PCOS were divided into the control group and combined group. The combined LH level in the combined group was lower than that in the control group after therapy, and the FSH level was higher than that in the control group. Conclusions The combination of letrozole and metformin with targeted nursing in the treatment of infertility patients with PCOS has improved clinical outcomes and high safety.

Source link: https://europepmc.org/article/MED/35368950


Effects of Low-Dose Spironolactone Combined with Metformin or Either Drug Alone on Insulin Resistance in Patients with Polycystic Ovary Syndrome: A Pilot Study.

Metformin and spironolactone alone can be used for the treatment of polycystic ovarian syndrome, and their combination can produce even better outcomes. This was a single-center, randomized, open-label, pilot study of patients with PCOS at the Third Affiliated Hospital of Guangzhou Medical University between 01/2014 and 01/2016 to compare the effects and safety of low-dose spironolactone, metformin, or both drug alone on insulin resistance and functional improvement in patients with PCOS. There were no differences in any parameters between the metformin and spironolactone groups. HOMA-IR in the combined group, after 12 weeks of therapy, was lower than in the metformin and spironolactone groups. Both metformin and spironolactone reduced HOMA-IR in patients with PCOS with PCOS, but there were no similarities between the two monotherapies. The combined therapy reduced HOMA-IR to a greater extent than monotherapy.

Source link: https://europepmc.org/article/MED/35345424


Synergic effect of bee pollen and metformin on proliferation and apoptosis of granulosa cells: Rat model of polycystic ovary syndrome

The most common cause of fertility problems related to metabolic disorders is polycystic ovary syndrome. Various studies reported the bee pollen as a phytoestrogens-rich substance. In the rat model of PCOS, this research sought to investigate the effects of BP and metformin alone and in combination with proliferation and apoptosis of granulosa cells. In this experimental study, 54 Wistar rats were given 2 mg of estradiol valerate intramuscularly, and six rats were considered as control. The preantral and antral follicles in the BP and metformin-treated PCOS group soared, and cystic follicles were greatly reduced, according to cystic follicles. In comparison to the PCOS group, the TNF, NO, and Ki67 expressions were reduced in the treated groups. On the other hand, apoptosis in the groups treated with BP increased in the treated group compared to the untreated group. The signs of PCOS were alleviated by metformin alone or synergistically with metformin.

Source link: https://europepmc.org/article/MED/IND607702316


Short period-administration of myo-inositol and metformin on hormonal and glycolipid profiles in patients with polycystic ovary syndrome: a systematic review and updated meta-analysis of randomized controlled trials.

Objectivia This meta-analysis aims to determine myo-inositol and the classical insulin sensitizer metformin in terms of efficacy and safety for treating women with polycystic ovary syndrome (PCO). To synthesize the effect sizes of individual trails, the random effects model was chosen to synthesize the effect sizes. Myo-ins may be more effective in lowering triglycerides levels and avoiding side effects than metformin, while no significant differences were found in other important metrics, such as total testosterone and sex hormone binding globulin.

Source link: https://europepmc.org/article/MED/35363325


Effect of acupuncture and metformin on insulin sensitivity in women with polycystic ovary syndrome and insulin resistance: a three-armed randomized controlled trial.

Does acupuncture improve insulin sensitivity in women with polycystic ovary syndrome or insulin resistance? Among women with PCOS and IR, acupuncture was not more efficient than metformin or sham acupuncture in increasing insulin sensitivity, according to a summary statement. acupuncture has been shown to have reduced side effects compared to metformin in women with PCOS and IR, and what is now unknown. Participants/materials, location, and methods Women aged 18 to 40 years with the PCOS and homeostasis model assessment of insulin resistance were randomly selected to receive real acupuncture plus placebo, metformin plus sham acupuncture plus placebo for four months, with an additional 3-month follow-up. When compared to baseline, the changes of HOMA-IR in the true acupuncture group, -1. 0 in the metformin group and -0. 3 in the sham acupuncture group were 0. 4 percent, respectively. The findings have larger ramifications True acupuncture did not enhance insulin sensitivity in women with PCOS and IR, but it is safer than metformin in improving glucose metabolism and has less side effects. Metformin had a greater risk of digestive abnormalities than acupuncture groups, and therefore acupuncture might have been a non-pharmacologic drug with low risk for women with PCOS.

Source link: https://europepmc.org/article/MED/34907435


Metformin ameliorates polycystic ovary syndrome in a rat model by decreasing excessive autophagy in ovarian granulosa cells via the PI3K/AKT/mTOR pathway.

PCOS affects approximately 6%-15% of all reproductive-age women around the world. Metformin, a common drug used to treat PCOS in patients, has positive results in lowering hyperandrogenism and inducing ovulation; however, the mechanism by which metformin improves PCOS are unclear. We first tested the presence of oxidative stress and the expression of autophagy-associated proteins and key proteins in the PI3K/AKT/mTOR pathway in ovarian granulosa cells with metformin, established PCOS' pathological recovery, and then evaluated the effects of metformin on ovarian granulosa cells using metformin. Our findings show that metformin improves PCOS in a rats model by reducing excessive autophagy in GCs via the PI3K/AKT/mTOR pathway, and that PCOS can be reduced by targeted reduction of excess autophagy in ovarian granulosa cells and PCOS.

Source link: https://europepmc.org/article/MED/35228471


Thyroid Status During Pregnancy in Women With Polycystic Ovary Syndrome and the Effect of Metformin.

Knowledge is lacking regarding the complex relationship between thyroid disease and PCOS during pregnancy. We investigated the thyroid function and its relationship with pregnancy complications in PCOS, as well as metformin therapy. From the first trimester to delivery, 288 pregnant women with PCOS were randomized to metformin or placebo. We measured serum thyroid stimulating hormone and free thyroxine at gestational week 5-12, 19, 32, 36, and 36, which are related to metformin therapy and pregnancy complications. A lower fT4 decrease during pregnancy correlated to less weight gain and reduced odds ratios for gestational diabetes, which was generally associated with reduced odds ratios. Conclusions: Metformin therapy during pregnancy was linked to less fT4 decrease in fT4 than placebo, though it did not affect TSH, despite knowing that it did not influence TSH.

Source link: https://europepmc.org/article/MED/35265033


Sitagliptin/metformin improves the fertilization rate and embryo quality in polycystic ovary syndrome patients through increasing the expression of GDF9 and BMP15: A new alternative to metformin (a randomized trial).

This research was designed to investigate the effects of sitagliptin/metformin, metformin, and sitagliptin in PCOS patients. In the treated groups, the serum levels of HOMA-IR and FAI decreased dramatically compared to the placebo group. Compared to the metformin and sitagliptin groups, the serum and the FF levels of leptin in the sitaformin group also decreased significantly in the sitaformin group. In addition, the serum and FF levels of AMH and MDA showed a significant decline in the sitagliptin and sitagliptin group relative to the placebo. In the cumulus cells, the mRNA expression and protein levels of GDF9 and BMP15 were elevated significantly in comparison to metformin and sitagliptin groups. The expression levels of GDF9 and BMP15 mRNA were positively linked to the fertilization rate and grade I embryos, as shown by the above.

Source link: https://europepmc.org/article/MED/35217236

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions